整合素α4在难治复发急性淋巴细胞白血病中的研究进展
Research Advances of Integrin Alpha 4 in Drug Resistant or Relapsed Acute Lymphoblastic Leukemia
摘要: 当下难治复发急性淋巴细胞白血病(ALL)不管在成人还是儿童中均面临着较差预后的治疗挑战，而整合素α4基本表达于所有淋巴细胞表面，且是参与细胞粘附介导耐药(CAM-DR)机制中重要组成部分，故本文将从CAM-DR在难治复发ALL中的作用、整合素α4介导的CAM-DR效应、拮抗整合素α4在治疗难治复发ALL的意义三方面展开综述，为治疗难治复发ALL病人提供一种新的治疗思路。
Abstract: Chemotherapeutic drug resistance or relapse in acute lymphoblastic leukemia (r/r ALL) is a chal-lenging problem, resulting in poor prognosis. Integrin alpha 4 plays a critical role in mechanism of cell adhesion-mediated drug resistance (CAM-DR), while expressing on most leukocyte surface broadly including lymphoblastic leukemia cell. We here review the mechanism of CAM-DR in r/r ALL, the role of integrin alpha 4 in mechanism of CAM-DR and the targeting of integrin alpha 4 as a novel strategy for treatment of r/r ALL.
文章引用：徐倚琪, 吴学东, 阮永胜. 整合素α4在难治复发急性淋巴细胞白血病中的研究进展[J]. 亚洲儿科病例研究, 2018, 6(4): 35-39. https://doi.org/10.12677/ACRP.2018.64006

参考文献

[1] Pui, C.H., Mullighan, C.G., Evans, W.E., et al. (2012) Pediatric Acute Lymphoblastic Leukemia: Where Are We Going and How Do We Get There? Blood, 120, 1165-1174.
[Google Scholar] [CrossRef] [PubMed]
[2] Parikh, S.A. and Litzow, M.R. (2014) Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Therapies under Development. Future Oncology, 10, 2201-2212.
[Google Scholar] [CrossRef] [PubMed]
[3] 阮永胜, 吴学东, 冯晓勤, 等. ALL-BFM95方案治疗儿童急性淋巴细胞白血病高危患儿的预后分析[J]. 中国当代儿科杂志, 2015(4): 327-331.
[4] 阮永胜, 吴学东. 儿童急性淋巴细胞白血病复发的研究进展[J]. 中华临床医师杂志(电子版), 2014(18): 3359-3363.
[5] Fragoso, R. and Barata, J.T. (2014) PTEN and Leukemia Stem Cells. Advances in Biological Regulation, 56, 22-29.
[Google Scholar] [CrossRef] [PubMed]
[6] Schofield, R. (1978) The Relationship between the Spleen Colo-ny-Forming Cell and the Haemopoietic Stem Cell. Blood Cells, 4, 7-25.
[7] Tabe, T. and Konopleva, M. (2014) Advances in Understanding the Leukaemia Microenvironment. British Journal of Haematology, 164, 767-778.
[Google Scholar] [CrossRef] [PubMed]
[8] Colmone, A., Amorim, M., Pontier, A.L., et al. (2008) Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells. Science, 322, 1861-1865.
[Google Scholar] [CrossRef] [PubMed]
[9] Hazlehurst, L.A., Argilagos, R.F. and Dalton, W.S. (2007) Beta1 Integrin Mediated Adhesion Increases Bim Protein Degradation and Contributes to Drug Resistance in Leukaemia Cells. British Journal of Haematology, 136, 269-275.
[Google Scholar] [CrossRef] [PubMed]
[10] 陈幸华, 高蕾, 张曦, 等. 新型白血病骨髓基质细胞黏附介导耐药模型构建的探索性研究[J]. 中华医学杂志, 2007, 87(20): 1380-1383.
[11] Mudry, R.E., Fortney, J.E., York, T., et al. (2000) Stromal Cells Regulate Survival of B-Lineage Leukemic Cells during Chemotherapy. Blood, 96, 1926-1932.
[12] Hynes, R.O. (2002) Integrins: Bidirectional, Allosteric Signaling Machines. Cell, 110, 673-687.
[Google Scholar] [CrossRef] 
[13] Streuli, C.H. and Akhtar, N. (2009) Signal Co-Operation between Integrins and Other Receptor Systems. Biochemical Journal, 418, 491-506.
[Google Scholar] [CrossRef] 
[14] Cabodi, S., Moro, L., Bergatto, E., et al. (2004) Integrin Regulation of Epi-dermal Growth Factor (EGF) Receptor and of EGF-Dependent Responses. Biochemical Society Transactions, 32, 438-442.
[Google Scholar] [CrossRef] [PubMed]
[15] Guo, W. and Giancotti, F.G. (2004) Integrin Signalling during Tumour Pro-gression. Nature Reviews Molecular Cell Biology, 5, 816-826.
[Google Scholar] [CrossRef] [PubMed]
[16] Tabe, Y., Jin, L., Tsutsumi-Ishii, Y., et al. (2007) Activation of Integrin-Linked Kinase Is a Critical Prosurvival Pathway Induced in Leukemic Cells by Bone Marrow-Derived Stromal Cells. Cancer Research, 67, 684-694.
[Google Scholar] [CrossRef] 
[17] Lim, C.J., Han, J., Yousefi, N., et al. (2007) Alpha4 Integrins Are Type I cAMP-Dependent Protein Kinase-Anchoring Proteins. Nature Cell Biology, 9, 415-421.
[Google Scholar] [CrossRef] [PubMed]
[18] Rivera Rosado, L.A., Horn, T.A., McGrath, S.C., et al. (2011) Association be-tween alpha4 Integrin Cytoplasmic Tail and Non-Muscle Myosin IIA Regulates Cell Migration. Journal of Cell Science, 124, 483-492.
[Google Scholar] [CrossRef] [PubMed]
[19] Fortney, J.E., Hall, B.M., Bartrug, L., et al. (2002) Chemotherapy Induces bcl-2 Cleavage in Lymphoid Leukemic Cell Lines. Leuk Lymphoma, 43, 2171-2178.
[Google Scholar] [CrossRef] [PubMed]
[20] Wang, L., Fortney, J.E. and Gibson, L.F. (2004) Stromal Cell Protection of B-Lineage Acute Lymphoblastic Leukemic Cells during Chemotherapy Requires Active Akt. Leukemia Research, 28, 733-742.
[Google Scholar] [CrossRef] [PubMed]
[21] Nwabo Kamdje, A.H. and Krampera, M. (2011) Notch Signaling in Acute Lymphoblastic Leukemia: Any Role for Stromal Microenvironment? Blood, 118, 6506-6514.
[Google Scholar] [CrossRef] [PubMed]
[22] Bertrand, F.E., Spengemen, J.D., Shelton, J.G., et al. (2005) Inhi-bition of PI3K, mTOR and MEK Signaling Pathways Promotes Rapid Apoptosis in B-Lineage ALL in the Presence of Stromal Cell Support. Leukemia, 19, 98-102.
[Google Scholar] [CrossRef] [PubMed]
[23] Jacamo, R., Chen, Y., Wang, Z., et al. (2014) Reciprocal Leukemia-Stroma VCAM-1/VLA-4-Dependent Activation of NF-kB Mediates Chemoresistance. Blood, 123, 2691-2702.
[Google Scholar] [CrossRef] [PubMed]
[24] Yu, Y., Schurpf, T. and Springer, T.A. (2013) How Natalizumab Binds and Antagonizes alpha4 Integrins. The Journal of Biological Chemistry, 288, 32314-32325.
[Google Scholar] [CrossRef] 
[25] Hsieh, Y.T., Gang, E.J., Geng, H., et al. (2013) Integrin alpha4 Blockade Sensitizes Drug Resistant pre-B Acute Lymphoblastic Leukemia to Chemotherapy. Blood, 121, 1814-1818.
[Google Scholar] [CrossRef] [PubMed]
[26] Schwab, N., Schneider-Hohendorf, T., Melzer, N., et al. (2017) Natalizumab-Associated PML Challenges with Incidence, Resulting Risk, and Risk Stratification. Neurology, 88, 1197-1205.
[Google Scholar] [CrossRef] 
[27] Shishido, S., Bönig, H. and Kim, Y.M. (2014) Role of Integrin Alpha4 in Drug Resistance of Leukemia. Frontiers in Oncology, 4, 99.
[Google Scholar] [CrossRef] [PubMed]
[28] Hsieh, Y.T., Gang, E.J. and Shishido, S.N. (2014) Effects of the Small-Molecule Inhibitor of Integrin A4, TBC3486, on Pre-B-ALL Cells. Leukemia, 28, 2101-2104.
[Google Scholar] [CrossRef] [PubMed]
[29] Ruan, Y., Gang, E.J., Kim, H.N., et al. (2016) AVA4746, an Orally Available, Clinical Grade Antagonist of Integrin Alpha 4, Sensitizes Pre-B Cell Acute Lymphoblastic Leukemia to Chemotherapy. Blood, 128, 2765.